Author: Lindsay Colin R Roxburgh Patricia Graham Janet
Publisher: Future Medicine
ISSN: 1479-6694
Source: Future Oncology, Vol.9, Iss.6, 2013-06, pp. : 825-829
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
A number of Phase II/III clinical trials have now been reported assessing the role of cetuximab use in combination with chemotherapy for the first-line treatment of metastatic colorectal cancer. Here we review the current position of cetuximab in this context from two important perspectives. First, we address whether clinicians should prioritize its use with oxaliplatin- or irinotecan-based chemotherapy doublets. Second, we review the trial evidence for the use of cetuximab in patients suffering from colorectal cancer with wild-type and mutant Ras.
Related content
By Modest Dominik P. Laubender Ruediger P. Stintzing Sebastian Giessen Clemens Schulz Christoph Haas Michael Mansmann Ulrich Heinemann Volker
Acta Oncologica, Vol. 52, Iss. 5, 2013-06 ,pp. :
By Sørbye Halfdan Berglund Åke Tveit Kjell Magne Øgreid Dagfinn Wanderås Eva Hoff Wentzel-Larsen Tore Dahl Olav Glimelius Bengt
Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. :